Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | PRNP | P04156 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2391348 | 1.00 | DPP4 (0.36) | DPP4ALDH1A1MAPTKDM4ELMNA | |
| SCHEMBL2391358 | 1.00 | DPP4 (0.36) | DPP4ALDH1A1MAPTKDM4ELMNA | |
| SCHEMBL30289156 | 0.80 | ALDH1A1 (0.44) | DPP4ALDH1A1MAPTKDM4ELMNA | |
| SCHEMBL2390691 | 0.80 | ALDH1A1 (0.44) | DPP4ALDH1A1MAPTKDM4ELMNA | |
| SCHEMBL8282635 | 0.76 | CYP3A4 (0.51) | DPP4ALDH1A1MAPTKDM4ECYP3A4 | |
| SCHEMBL4235697 | 0.69 | ALDH1A1 (0.44) | ALDH1A1MAPTKDM4ELMNACYP3A4 | |
| SCHEMBL4239996 | 0.69 | ALDH1A1 (0.44) | ALDH1A1MAPTKDM4ELMNACYP3A4 | |
| SCHEMBL3670384 | 0.69 | ALDH1A1 (0.44) | ALDH1A1MAPTKDM4ELMNACYP3A4 | |
| SCHEMBL3670385 | 0.69 | ALDH1A1 (0.44) | ALDH1A1MAPTKDM4ELMNACYP3A4 | |
| SCHEMBL4235695 | 0.69 | ALDH1A1 (0.44) | ALDH1A1MAPTKDM4ELMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073898-B2 | Crystalline form of an inhibitor of MDM2/4 and p53 interaction | NOVARTIS AG (CH) | 2015-07-07 | — | — | US | disclosed |
| US-9073898-B2 | Crystalline form of an inhibitor of MDM2/4 and p53 interaction | NOVARTIS AG (CH) | 2015-07-07 | — | — | US | disclosed |
| US-9073898-B2 | Crystalline form of an inhibitor of MDM2/4 and p53 interaction | NOVARTIS AG (CH) | 2015-07-07 | — | — | US | disclosed |
| US-9051279-B2 | Substituted isoquinolinones and quinazolinones | NOVARTIS AG (CH) | 2015-06-09 | — | — | US | disclosed |
| US-9051279-B2 | Substituted isoquinolinones and quinazolinones | NOVARTIS AG (CH) | 2015-06-09 | — | — | US | disclosed |
| US-9051279-B2 | Substituted isoquinolinones and quinazolinones | NOVARTIS AG (CH) | 2015-06-09 | — | — | US | disclosed |
| EP-2721008-B1 | HYDROXY SUBSTITUTED ISOQUINOLINONE DERIVATIVES AS P53 (MDM2 OR MDM4) INHIBITORS | NOVARTIS AG (CH) | 2015-04-29 | — | — | EP | disclosed |
| US-8969351-B2 | Crystalline form of an inhibitor of MDM2/4 and p53 interaction | NOVARTIS AG (CH) | 2015-03-03 | — | — | US | disclosed |
| US-8969351-B2 | Crystalline form of an inhibitor of MDM2/4 and p53 interaction | NOVARTIS AG (CH) | 2015-03-03 | — | — | US | disclosed |
| US-8969351-B2 | Crystalline form of an inhibitor of MDM2/4 and p53 interaction | NOVARTIS AG (CH) | 2015-03-03 | — | — | US | disclosed |
| US-8440693-B2 | Substituted isoquinolinones and quinazolinones | NOVARTIS AG (CH) | 2013-05-14 | — | — | US | disclosed |
| US-8440693-B2 | Substituted isoquinolinones and quinazolinones | NOVARTIS AG (CH) | 2013-05-14 | — | — | US | disclosed |
| EP-2516009-A1 | SUBSTITUTED ISOQUINOLINONES AND QUINAZOLINONES | Novartis AG (CH) | 2012-10-31 | — | — | EP | disclosed |
| WO-2012066095-A1 | CRYSTALLINE FORM OF AN INHIBITOR OF MDM2/4 AND P53 INTERACTION | NOVARTIS AG (CH) | 2012-05-24 | — | — | WO | disclosed |
| US-20120129871-A1 | Crystalline form of an inhibitor of MDM2/4 and p53 interaction | NOVARTIS AG (CH) | 2012-05-24 | — | — | US | disclosed |
| US-20120129871-A1 | Crystalline form of an inhibitor of MDM2/4 and p53 interaction | NOVARTIS AG (CH) | 2012-05-24 | — | — | US | disclosed |
| US-20120129871-A1 | Crystalline form of an inhibitor of MDM2/4 and p53 interaction | NOVARTIS AG (CH) | 2012-05-24 | — | — | US | disclosed |
| US-20110230457-A1 | Substituted Isoquinolinones and Quinazolinones | NOVARTIS AG (CH) | 2011-09-22 | — | — | US | disclosed |
| US-20110230457-A1 | Substituted Isoquinolinones and Quinazolinones | NOVARTIS AG (CH) | 2011-09-22 | — | — | US | disclosed |
| US-20110230457-A1 | Substituted Isoquinolinones and Quinazolinones | NOVARTIS AG (CH) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230457-A1 | Substituted Isoquinolinones and Quinazolinones | MDM4, MDM2, TP53 | DPP4 2499/4885ALDH1A1 3726/4885MAPT 957/4885 |
| US-20120129871-A1 | Crystalline form of an inhibitor of MDM2/4 and p53 interaction | MDM4, TP53, TP53BP1 | DPP4 349/4885ALDH1A1 4048/4885MAPT 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.